Skip to main content

Table 4 Total healthcare costs (excluding treatment acquisition) for bedaquiline plus BR versus BR in the analyzed countries

From: Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries

  Estonia Russia South Africa Peru China Philippines India
Cohort
 Populationa, cases (n) 38 6,537 6,494 564 826 11 20,763
Hospitalization costs (at 100% hospitalization), US$ totalb/per patientc
 Bedaquiline + BR 2,515,318/66,193 400,933,524/61,333 85,584,735/13,179 8,505,448/15,080 7,792,452/9,434 35,660/3,242 4,892,107/236
 BR only 3,780,243/99,480 596,419,985/91,238 129,930,717/20,008 12,699,038/22,516 11,177,776/13,532 52,799/4,800 7,376,327/355
Outpatient care, US$ totalb/per patientc
 Bedaquiline + BR 23,858/628 1,716,115/263 1,221,043/188 47,999/85 77,975/94 394/36 1,740,459/84
 BR only 17,667/465 1,109,759/170 1,144 148/20,008 31,283/55 72,985/88 249/23 1,979,948/95
Monitoring costs, US$ totalb/per patientc
 Bedaquiline + BR 66,887/1,760 11,449,710/1,752 7,778,834/1,198 721,800/1,280 930,012/1,126 9,182/835 15,202,670/732
 BR only 69,860/1,838 10,165,718/1,555 6,808,367/1,048 682,575/1,210 1,019,445/1,234 8,989/817 16,650,529/802
Total healthcare costs (excluding treatment acquisition costs), US$ totalb/per patientc
 Bedaquiline + BR 2,606,062/68,581 414,099,348/63,347 94,584,612/14,565 9,275,248/16,445 8,800,439/10,654 45,236/4,112 21,835,236/1,052
 BR only 3,867,769/101,783 607,695,462/92,962 137,883,232/21,232 13,412,896/23,782 12,270,205/14,855 62,037/5,640 26,006,804/1,253
 Incremental health care cost-savings (excluding acquisition costs) (bedaquiline + BR vs. BR), US$ totalb/per patientc 1,261,707/33,202 193,596,114/29,615 43,298,620/6,667 4,137,648/7,337 3,469,766/4,201 16,801/1,528 4,171,568/201
  1. BR background regimen, TB tuberculosis, US United States
  2. aPopulation cohort: Russia, China, Philippines: New lab-confirmed MDR-TB cases in 2012 [31]; South Africa: Total number of patients started on MDR-TB treatment in 2012 [31]; Estonia, Peru: laboratory-confirmed MDR-TB cases in 2012 [31]; India: Total number of patients started on MDR-TB treatment in 2013 [2]; bTotal costs (inflated to US$ 2013) reflect costs for the entire cohort of patients; cper patient costs (inflated to US$ 2013) are calculated by dividing the total costs by the population cases (n)